What’s new in the Australian Injectable Drugs Handbook (AIDH) 10th edition
Every monograph has been reviewed and updated, with more than 500 featured and 40 new monographs
55 reviewers contributed to the monograph updates, reviewing manufacturer information, published studies and considering user feedback
Ambulatory antimicrobial therapy information was reviewed and updated in 26 monographs, with new information in 8 monographs from 5 new stability studies
The AIDH editorial committee together with the AdPha Emergency Medicine Leadership Committee have provided summary guidance on the preparation and administration of the first antimicrobial dose for adults with sepsis. Faster rates of administration of the first dose in sepsis are available in 7 monographs.
A new table of potassium chloride premixed infusion bags to guide the safe selection and administration of potassium
Clinical and practical resources reviewed and updated
A new section on IV access and equipment, including midline catheters, filter needles and glass ampoules and compatible containers and infusion sets
Compatibility information reviewed and updated, including new information in over 40 monographs from 8 new studies
New paediatric administration advice in agalsidase alfa and beta, and isavuconazole
New hazard warnings for apomorphine and belatacept
Updated room temperature stability for neuromuscular blockers
Updated compatible container and infusion set information:
- Cabazitaxel
- Carmustine
- Clonazepam
- Diazepam
- Docetaxel
- Etoposide
- Letermovir
- Paclitaxel
Monograph title changes to be aware of:
- Chorionic gonadotropin to Choriogonadotropin
- Ephedrine to ephedrine hydrochloride and ephedrine sulfate
- Insulin for subcutaneous use only to Insulin biphasic, intermediate and long-acting
- Insulin for subcutaneous or IV use to Insulin short-acting and rapid-acting
- Paclitaxel NAB to Nab-paclitaxel
Details of significant changes
- Aciclovir (new ambulatory therapy information)
- Adenosine (new stability data for intracoronary injection)
- Alemtuzumab (additional infusion solution stability data for MabCampath)
- Alteplase (new preparation, stability and updated administration information)
- Amiodarone (additional stability information)
- Amphotericin liposomal (updated infusion time for doses more than 5mg/kg)
- Amoxicillin (updated IV injection advice)
- Ampicillin (additional ambulatory therapy stability information, updated IV injection advice)
- Anakinra (new information for IV administration)
- Anidulafungin (inclusion of preparation instructions for higher doses)
- Argipressin (new stability information)
- Aztreonam (updated ambulatory therapy stability information, extended infusion advice)
- Benzathine benzylpenicillin (updated based on available products during shortage)
- Benzylpenicillin sodium (additional part dosing advice)
- Caspofungin (infusion advice for doses over 70 mg)
- Cefepime (updated ambulatory therapy stability information)
- Cefiderocol (new ambulatory therapy information)
- Ceftazidime (updated ambulatory therapy stability information)
- Ceftazidime with avibactam (updated ambulatory therapy stability information, extended infusion advice)
- Cemipimab (updated stability information)
- Chlorpromazine (updated infusion advice)
- Ciprofloxacin (updated infusion advice)
- Clonazepam (updated stability information)
- Dacarbazine (updated stability information)
- Dalteparin (updated infusion advice)
- Danaparoid (updated infusion advice)
- Daptomycin (updated infusion advice)
- Dexmedetomidine (updated preparation advice)
- Doxorubin pegylated liposomal (updated infusion advice)
- Fat emulsion (updated filter advice)
- Fluconazole (updated infusion advice for adults and children)
- Flucloxacillin (updated infusion advice)
- Foscarnet (updated infusion advice)
- Gentamicin (updated IV injection advice)
- Hydromorphone (updated infusion advice)
- Hydroxocobalamin (updated infusion advice)
- Iron polymaltose (updated infusion advice)
- Labetolol (updated stability information)
- Magnesium sulfate (updated infusion advice)
- Meropenem (updated ambulatory therapy stability information, IV injection and continuous infusion advice)
- Methylene blue (updated infusion advice)
- Neostigmine (new infusion advice)
- Oxaliplatin (updated infusion advice)
- Pantoprazole (updated stability information)
- Pembrolizumab (updated stability information)
- Phenylephrine (updated infusion advice)
- Piperacillin and tazobactam (updated ambulatory therapy stability information and continuous infusion advice)
- Polatuzumab vedotin (updated stability information)
- Ravulizumab (inclusion of preparation for supplemental doses)
- Rituximab (updated infusion advice)
- Sodium valproate (concentration of the reconstituted solution)
- Tacrolimus (updated stability information)
- Tigecycline (new ambulatory therapy stability and administration information)
- Tobramycin (updated IV injection advice)
- Trimethoprim with sulfamethoxazole (inclusion of preparation information for doses up to 480/2400 mg)
New monographs (40)
- Amivantamab
- Belantamab mafodotin
- Bimekizumab
- Burosumab
- Cabotegravir
- Canakinumab
- Daunorubicin & cytarabine liposomal
- Dexrazoxane
- Difelikefalin
- Donanemab
- Dostarlimab
- Edaravone
- Elranatamab
- Enfortumab vedotin
- Epcoritamab
- Foslevodopa and foscarbidopa
- Fosnetupitant and palonosetron
- Glofitamab
- Imlifidase
- Landiolol
- Lecanemab
- Lenacapavir
- Lurbinectedin
- Mecasermin
- Mogamulizumab
- Nelarabine
- Nirsevimab
- Potassium chloride premixed bags
- Rozanolixizumab
- Spesolimab
- Talquetamab
- Tarlatamab
- Tebentafusp
- Teclistamab
- Tirzepatide
- Tislelizumab
- Toripalimab
- Tremelimumab
- Ublituximab
- Vutisiran